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Bringing Clinicians and Patients to the Starting Line*Michael E. Farkouh, MD, MSCSEE PAGE 959T he recent American College of Cardiology/American Heart Association clinical practiceguidelines for the treatment of lipids have
been received with a great deal of fanfare. The debate
over the most effective risk tool to estimate the
10-year cardiovascular risk remains an ongoing con-
troversy. There is widespread consensus that we
need to identify high-risk primary prevention pa-
tients for consideration of more aggressive therapy.
The new guidelines introduce Pooled Cohort
Equations (1), which differ from the more traditional
Adult Treatment Panel III calculator, which was based
on Framingham. The most important changes have
been the adoption of stroke as a primary outcome
measure for atherosclerotic cardiovascular disease
(ASCVD), the adoption of sex- and race-speciﬁc
models in addition to the traditional cardiovascular
risk factors, and the inclusion of diabetes as an
important determinant. These modiﬁcations are
important advances as we bring risk prediction to a
diverse population and have been validated in an
analysis from the REGARDS (Reasons for Geographic
and Racial Differences in Stroke) prospective obser-
vational study (2).
In general, many analyses suggest that physicians
do a poor job of cardiovascular risk prediction. When
U.S. physicians were studied, there was low concor-
dance between the cardiovascular risk calculated by
the Framingham risk score and physicians’ percep-
tions of their patients’ risk for developing coronary*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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physicians did a particularly poor job of estimating
the cardiovascular risk in elderly patients, in that
their risk was underestimated. Even more discon-
certing is that only 40% of family physicians, in-
ternists, and cardiologists used the assessment tool
when assessing the prognosis of cardiovascular risk
(4). Therefore, regardless of which tool one prefers, it
is very clear that we are underutilizing effective
means available to educate our patients about their
future risk of ASCVD.In this issue of the Journal, Karmali et al. (5) report
on an evaluation of the distribution of 10-year risk for
ASCVD using hypothetical patient data in the Pooled
Cohort Equations. An ASCVD risk of 7.5% risk over 10
years was believed to demonstrate a threshold at
which initiation of statin therapy could be consid-
ered. In their analysis, they were able to demonstrate
that for non-Hispanic white and African-American
men and women, the age at which a given individ-
ual would cross over the 7.5% threshold varied ac-
cording to the number and degree of risk factors.
Even when optimal risk proﬁles were present,
including total cholesterol of 170 mg/dl or less, high-
density lipoprotein cholesterol of 50 mg/dl or more,
untreated systolic blood pressure of 110 mm Hg, and
no diabetes or smoking, the age to reach the 7.5%
threshold ranged from 65 years in non-Hispanic
white men to 70 years in African-American men and
women and 75 years in non-Hispanic white women.
Overall, the use of this risk calculator will substan-
tially increase the number of all Americans, including
women and African Americans, who will be consid-
ered potential candidates for statin therapy (6).
The inclusion of diabetes in the equation could
also have a major public health impact. For patients
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970without blood pressure treatment in the 4 major sex
and race groups, all but non-Hispanic white women
would reach the 7.5% threshold by the age of 55
years. If blood pressure is treated, all 3 major groups
except non-Hispanic white women would reach the
threshold by the age of 50 years. Prior risk calculators
that exclude diabetes could signiﬁcantly underesti-
mate ASCVD risk, particularly in light of the obesity
epidemic.
Perhaps the greatest lesson from this controversy
and the evaluation of the modeling of the Pooled
Cohort Equation is the emphasis placed on the
starting line, the opportunity to have an informed
discussion with our patients. It reafﬁrms that medi-
cine is an art as much as a science. By beginning at
a point of providing our patients with an under-
standing of their 10-year risk of ASCVD, we then
allow the patient to understand the magnitude of
the problem and the potential interventions that
may lie ahead. No risk calculator is perfect, but we
can start with one built on evidence and consensus.
Some also have questioned the 7.5% 10-year
threshold, which was chosen arbitrarily and may
vary depending on patient and physician preference.
In some healthcare systems, a 10-year risk of 10%
may be more appropriate, particularly for patients
who are at risk of adverse effects of therapies such as
statins. For others who are younger and whose car-
diovascular health is at greater risk because of a
positive family history, for example, a 5% threshold
may be more suitable.
The next logical step in the implementation of
the risk calculator is the appropriate adoption of
therapies to prevent ASCVD. At the starting line,
clinicians should be prepared to initiate a discus-
sion about the beneﬁts and risks of statins. The
current guidelines are a mechanism to begin such
a discussion with our patients, but they are not acommitment to intervention. Across the spectrum
of evidence from observational studies to clinical
trials to practice guidelines, knowledge translation
is the underpinning of the clinician-patient dia-
logue. Every patient has a unique risk proﬁle and
demographic background that will inﬂuence his or
her decision making.
The use of hypothetical patients to evaluate a risk
score is not unusual and allows for a full evaluation
of the range of risk for ASCVD. There are a number
of settings in which hypothetical patient data are
used to model risk, both for evaluating physician
behavior and for educating patients. The modeling of
changes in multiple risk factors simultaneously has
the potential to miss important interactions between
risk factors, which can lead to errors in predicting
risk; however, without hypothetical data, it is difﬁ-
cult to fully deﬁne the full impact of a risk calculator.
In the end, the ﬁndings of the study by Karmali
et al. (5) will enhance the clinician-patient discussion
and afford us the opportunity to educate our pa-
tients. It allows us to bring a viable model to the
patient but will not lead to intervention for all
patients who attain a threshold of 7.5%. Patients,
aided by knowledge provided by their physicians,
should make their decisions regarding statin therapy
using multiple considerations, including their own
preferences and by weighing the adverse effects
against any perceived beneﬁts of intervention. Ulti-
mately, if we are to improve the health of Americans
and decrease the burden of disease from ASCVD,
we need to bring our patients, and ourselves, to the
starting line.
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